Abstracts tagged "interleukins (IL) and rheumatoid arthritis (RA)"

Abstract Number: 2331 • 2012 ACR/ARHP Annual Meeting
The Effects of Anti–Tumor Necrosis Factor Agents On the Expansion of T Helper-Type 17 Cells Driven by Lipopolysaccharide-Stimulated Monocytes
Gianluca Fossati¹, Louise Healy¹ and Andrew Nesbitt², ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, SLough, United Kingdom
Background/Purpose: T helper-type 17 (Th17) cells are proinflammatory CD4+ cells characterized by the production of Interleukin-17 (IL-17).There is evidence that IL-17 and other cytokines which…
Abstract Number: 1802 • 2012 ACR/ARHP Annual Meeting
Interleukin-29 Modulates Proinflammatory Cytokine Production in Synovial Inflammation of Rheumatoid Arthritis
Miaojia Zhang, Fang Wang, Lingxiao Xu and Wenfeng Tan, Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China
Background/Purpose: The immunoregulatory function of interleukin (IL)-29 has recently been recognized. However, little is known about the involvement of IL-29 in the pathogenesis of rheumatoid…
Abstract Number: 1784 • 2012 ACR/ARHP Annual Meeting
Dual Function of Interleukin-33 in Fibroblast-Like Synoviocytes in Patients with Rheumatoid Arthritis
Min W. So¹, Bon S. Koo¹, You J. Kim¹, You-G Kim¹, Wook J. Seo², Chang-K Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: IL-33 is a new member of the IL-1 cytokine family. Recent studies in an animal model of murine collagen-induced arthritis and human rheumatoid arthritis…
Abstract Number: 1796 • 2012 ACR/ARHP Annual Meeting
Anti-IL-20 Targets Local Tissue Inflammation As Opposed to Systemic Inflammation
Amanda L. Blasius¹, Joshua N. Beilke¹, Hal Blumberg¹, John Bui¹, Jennifer H. Cox¹, Tom Cox¹, Heidi J. Jessup¹, Phillip L. Kong¹, Steven D. Levin¹, Valerie H. Odegard¹, Jason A. Stucky¹, Evan P. Thomas¹, Joseph A. Wahle¹ and John Rømer², ¹Biopharmaceuticals Research Unit, Novo Nordisk Inflammation Research Center, Seattle, WA, ²Biopharmaceuticals Research Unit, Novo Nordisk, Måløv, Denmark
Background/Purpose: In a recent Phase 2a clinical trial in patients with rheumatoid arthritis, the novel human anti-IL-20 monoclonal antibody NNC0109-0012 was shown to reduce…
Abstract Number: 1339 • 2012 ACR/ARHP Annual Meeting
A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Alan J. Kivitz², Frank Wagner³, Jeffrey A. Feinstein⁴, Uwe Fuhr⁵, Jürgen Rech⁶, Jagdev Sidhu⁷, Philip L. Hill⁸, Ruth Oliver⁸ and Kosmas Kretsos⁹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³Charité Research Org GmbH, Berlin, Germany, ⁴San Antonio, TX, ⁵Hospital of the University of Cologne (AöR), Köln, Germany, ⁶Medizinische Klinik 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷CSL Limited, Parkville, Australia, ⁸UCB Celltech, Slough, United Kingdom, ⁹UCB, Slough, United Kingdom
Background/Purpose: Olokizumab is a novel IL-6 inhibitor that selectively blocks the final assembly of the IL-6 signaling complex (gp80+gp130+IL-6). We report the safety, PK, and…
Abstract Number: 1195 • 2012 ACR/ARHP Annual Meeting
Identification of Follicular Helper T Cells As a Novel Cell Population Potentially Involved in the Pathogenesis of Rheumatoid Arthritis
Sharon Ing¹, Anika Alarakhia¹, Elvira Lindwall¹, Austin Fraser¹, Jerald M. Zakem¹, William E. Davis¹, Tamika A. Webb-Detiege¹, Robert Quinet¹ and Xin Zhang², ¹Rheumatology, Ochsner Medical Center, New Orleans, LA, ²Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
Abstract Number: 65 • 2012 ACR/ARHP Annual Meeting
Serum Inflammatory Biomarkers Correlated Stronger with a Panel of Serum Steroid and Pituitary Hormones in a Cohort of Pre-Rheumatoid Arthritis (pre-RA) Than in Non-RA Control (CN) Subjects
Alfonse T. Masi¹, Kevin B. Elmore¹, Azeem A. Rehman¹, Jean C. Aldag¹ and Robert T. Chatterton², ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Obstetrics and Gynecology and Physiology, Northwestern University, Chicago, IL
Background/Purpose: Inflammatory cytokines influence steroid hormone production in tissue culture and affect serum levels and synovial fluid of active RA patients. Inflammatory biomarker and hormonal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].